Prurigo Nodularis Treatment Market By Product (Antihistamines, Capsacin Cream, Corticosteroids), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), & Region for 2024-2031

Prurigo Nodularis Treatment Market Valuation – 2024-2031

The Prurigo Nodularis (PN) therapy market is developing in response to the condition’s increasing prevalence and rising awareness among healthcare practitioners and patients. Prurigo nodularis is a persistent skin illness that causes itchy nodules and has a major impact on a patient’s quality of life. Over the last decade, there has been an increase in the number of diagnosed cases, partially due to improved diagnostic procedures and increased recognition of the disorder by dermatologists and general practitioners by enabling the market to surpass a revenue of USD 1.30 Billion valued in 2024 and reach a valuation of around USD 1.90 Billion by 2031.

The increasing use of telemedicine and digital health platforms makes dermatological consultations and treatments more accessible which contributes to the growing demand for PN therapies. As a result, the PN treatment market is predicted to expand significantly driven by a combination of rising illness prevalence, therapeutic improvements, and improved patient access to healthcare services by enabling the market to grow at a CAGR of 5.30% from 2024 to 2031. 

Prurigo Nodularis Treatment MarketDefinition/ Overview

Prurigo nodularis (PN) is a chronic skin disorder distinguished by very irritating nodules that are frequently caused by persistent scratching and inflammation. Prurigo nodularis treatment focuses on symptom relief, itch management, and addressing underlying causes to enhance the patient’s quality of life. Topical therapies are one of the most common methods for treating PN. Corticosteroids, calcineurin inhibitors, and capsaicin lotions are frequently used to treat inflammation and itching.

Prurigo nodularis (PN) is a persistent skin ailment that causes itchy nodules and has a major influence on a patient’s quality of life. Prurigo nodularis is treated using a variety of techniques focused on symptom management, itch relief, and skin lesion improvement. Topical therapies are one of the most common applications for PN therapy. These include corticosteroids, calcineurin inhibitors, and capsaicin creams.

The future of PN management will most likely involve an integrated approach that combines pharmacological and non-pharmacological techniques. As more is learned about the psychological impact of PN, comprehensive treatment strategies that include behavioral therapy, stress management, and lifestyle changes are becoming more widely accepted.

Will Increasing Demand for Capsaicin Cream Influence the Product Segment?

The growing demand for capsaicin cream is a major driver in the prurigo nodularis treatment market, particularly within the product segment. Capsaicin, derived from chili peppers has shown promise in treating the severe itching associated with prurigo nodularis. The increasing prevalence of prurigo nodularis is a major driver of this demand. According to research published in the Journal of the American Academy of Dermatology, the estimated prevalence of PN in the United States is 72 instances per 100,000 individuals. This equates to roughly 230,000 people impacted by this illness in the United States alone. According to the National Eczema Association, PN affects around one in every 4,000 people in the general community demonstrating its widespread prevalence.

According to the National Center for Biotechnology Information (NCBI) in a clinical trial, 33% of patients receiving capsaicin cream reported a significant reduction in pruritus compared to only 7% in the placebo group. This illustrates capsaicin’s potential usefulness in treating PN symptoms. Furthermore, the growing interest in natural and over-the-counter medicines is driving up the market for capsaicin cream. The American Academy of Dermatology points out that topical capsaicin is available without a prescription making it a viable alternative for many people.

Will Lack of Qualified Healthcare Professionals Hamper the Prurigo Nodularis Treatment Market?

The prurigo nodularis treatment market may be hampered by a lack of skilled healthcare practitioners, however, various factors may mitigate this potential barrier. One major factor is the rising global prevalence of prurigo nodularis (PN). While exact numbers are limited due to underdiagnosis, research indicates that PN affects roughly 72 per 100,000 persons in the United States. The increased frequency necessitates a greater demand for treatment choices and professionals. Furthermore, advances in diagnostic procedures are enhancing the detection of PN patients. For example, a 2022 study published in the Journal of the American Academy of Dermatology discovered that dermoscopy improved diagnostic accuracy for PN by 23% when compared to clinical examination alone.

This significant economic impact is expected to drive investment in treatment development and specialized training. Furthermore, the FDA’s approval of dupilumab for PN therapy in 2022 has raised awareness and interest in this market area. According to the National Eczema Association, dupilumab showed a 60% reduction in itch severity in clinical studies, potentially enhancing the quality of life for many PN sufferers. While the scarcity of healthcare personnel remains a worry, several market factors may assist in offsetting its effects. Despite labor issues, increasing disease awareness, economic incentives, and treatment improvements should attract more specialists to the sector and drive market expansion. However, addressing the healthcare personnel deficit is critical to fully fulfilling the market’s potential.

Category-Wise Acumens

Will Widespread Use and Trust in Corticosteroids Influence the Product Segment?

Corticosteroids dominate the market owing to their demonstrated usefulness in regulating inflammation and lowering itching caused by the illness. Dermatologists frequently prescribe corticosteroids as the first line of treatment. They are available in topical, oral, and injectable forms. They operate by inhibiting the immunological response that causes itchy nodules resulting in great alleviation for patients. Topical corticosteroids are especially popular because they may be applied directly to the afflicted areas providing localized treatment with less systemic adverse effects than oral or injectable alternatives. Corticosteroids’ broad use and trust supported by multiple clinical research and decades of medical practice solidifies their dominance in the PN therapy market.

Corticosteroids’ dominance in the PN therapy market is driven not only by their efficacy but also by their availability. These drugs are readily available and come in a variety of dosages and formulations making them appropriate for different stages and severity levels of PN. This flexibility enables healthcare providers to adjust treatment strategies to particular patient demands, hence improving treatment outcomes. Furthermore, corticosteroids are frequently covered by insurance programs which reduces patients’ financial burden and encourages treatment adherence.

Will the Rising Preference for Medications Drive Growth in the Distribution Channel Segment?

The retail pharmacies category is expected to have the highest compound annual growth rate (CAGR) in the prurigo nodularis treatment market over the forecast period. This dominance is partly due to an increasing propensity for obtaining pharmaceuticals from retail pharmacies which is heavily affected by their accessibility and convenience. Retail pharmacies are frequently more accessible to patients than hospitals or online pharmacies as they have longer hours and are placed in convenient neighborhood locations. This makes them the first choice for many people who need fast relief from the symptoms of prurigo nodularis which can be quite uncomfortable and debilitating.

Retail pharmacies frequently offer numerous incentives to attract patients such as discounts and loyalty programs. These cost-cutting approaches are especially tempting to patients who need long-term treatment for chronic illnesses such as prurigo nodularis. The economic benefits provided by retail pharmacies can greatly lessen patient’s financial burden encouraging them to continue their therapy uninterrupted. This is especially critical in the treatment of prurigo nodularis where strict adherence to prescribed medication regimens is required for successful symptom control and flare-up avoidance.

Gain Access into Prurigo Nodularis Treatment Market Report Methodology

Country/Region-wise Acumens

Will the Rising Disease Awareness Drive the Growth in the Asia Pacific Region?

The Asia Pacific region is expected to see considerable growth in the Prurigo Nodularis (PN) treatment market owing to increase in illness awareness and improved healthcare infrastructure. As more people and healthcare providers become aware of the signs and effects of PN, there is a greater desire for effective treatments. According to research published in the Journal of the American Academy of Dermatology, the frequency of PN in Asia varies between 0.1% and 3.8% of the population depending on the country and demography. This incidence combined with the massive population bases in countries such as China and India indicates a significant potential market for PN treatments.

Organizations such as the International Forum for the Study of Itch (IFSI) and the Asian Academy of Dermatology and Venereology (AADV) have played an important role in educating both patients and healthcare professionals about PN contributing to the increase in disease awareness. According to World Health Organization (WHO) research, dermatological disorders including PN are becoming more widely recognized as serious health concerns in the Asia Pacific region with a 15% increase in reported cases in the last five years.

Will the Rising Healthcare Expenditures and a Growing Patient Population Boost the Market in the North American Region?

The prurigo nodularis (PN) treatment market in North America is expected to increase significantly owing to many main factors. One of the main drivers is the region’s increase in healthcare expenses. According to the Centers for Medicare and Medicaid Services (CMS), U.S. healthcare spending will exceed USD 4.3 Trillion in 2021, up 2.7% from 2020. This trend of increase in healthcare spending is anticipated to continue with forecasts indicating that it would reach USD 6.2 Trillion by 2028. The significant investment in healthcare infrastructure and research creates an enabling environment for the development and implementation of novel PN treatments. Furthermore, the expanding patient population is a key driver of market expansion.

Another key cause is the growing awareness and diagnosis of PN. The National Eczema Association has been actively striving to increase awareness of PN and other associated disorders resulting in better recognition and diagnosis. This, together with developments in diagnostic procedures is expected to enhance the identified patient pool accelerating market expansion. The market also benefits from ongoing R&D initiatives. The National Institutes of Health (NIH) has financed various research on PN, and clinicaltrials.gov lists more than 20 active or recruiting clinical trials for PN treatments as of 2024. This extensive pipeline of prospective therapies is projected to provide more effective treatment alternatives, hence supporting market growth.

Competitive Landscape

The prurigo nodularis treatment market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the prurigo nodularis treatment market include

• Bayer AG
• Galderma SA (Nestle Skin Health Company)
• Pfizer, Inc.
• Sanofi SA
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline Plc
• VYNE Therapeutics, Inc.
• Trevi Therapeutics, Inc
• Merck & Co., Inc.
• Novartis AG
• Celgene Corporation
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson

Latest Developments

• In February 2023, Pfizer is planning an unprecedented number of pharmaceutical launches with the corporation expected to release 19 new drugs over the next 18 months.
• In June 2023, Novartis announced that it has agreed to acquire Chinook Therapeutics, a Seattle, WA-based clinical-stage biopharmaceutical company with two high-value, late-stage medicines in development for rare, severe chronic kidney diseases. The agreed-upon deal is subject to customary closing conditions and is fully consistent with Novartis’ strategy to focus on innovative medicines. It will significantly expand its renal portfolio, complementing the existing pipeline.

Report Scope

Prurigo Nodularis Treatment Market, By Category

Product

• Antihistamines
• Capsaicin Cream
• Corticosteroids
• Emollients
• Others

Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.